✦ LIBER ✦

Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer

✍ Scribed by G. Falchook; B. Goff; R. Kurzrock; H. Gray; L. Martin; R. Coleman; H. Xiao; X. Zhou; E. Benaim; R. Schilder

Book ID: 113963626
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 132 KB
Volume: 125
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2011.12.071

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of MLN8237 (alisertib), a

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

✍ Ursula A. Matulonis; Sudarshan Sharma; Sharad Ghamande; Michael S. Gordon; Salva 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 408 KB

Phase 1–2 study of docetaxel plus aflibe

Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

✍ Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 208 KB

OCEANS: A Randomized, Double-Blind, Plac

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

✍ Aghajanian, C.; Blank, S. V.; Goff, B. A.; Judson, P. L.; Teneriello, M. G.; Hus 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 348 KB

A phase II evaluation of the potent, hig

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

✍ Coleman, R.; Sill, M.; Aghajanian, C.; Gray, H.; Tewari, K.; Rubin, S.; Rutherfo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 292 KB

A phase II trial of intraperitoneal EGEN

A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: A GOG study

✍ Alvarez, R.D.; Sill, M.; Davidson, S.A.; Muller, C.; Bender, D.P.; DeBernardo, R 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 94 KB

A phase II trial of intraperitoneal EGEN

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study

✍ Alvarez, Ronald D.; Sill, Michael W.; Davidson, Susan A.; Muller, Carolyn Y.; Be 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 308 KB